Patents by Inventor Patrick J. Lupardus

Patrick J. Lupardus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL2RB/IL2G SYNTHETIC CYTOKINES
    Publication number: 20250019453
    Abstract: Provided herein are IL2R binding molecules that bind to IL2Rb and IL2Rg and comprise an IL2Rg sdAb and an anti-IL2Rg VHH antibody.
    Type: Application
    Filed: August 9, 2024
    Publication date: January 16, 2025
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus, Rene De Waal Malefyt, Sandro Vivona
  • IL27RAlpha binding molecules and methods of use
    Patent number: 12157773
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL27R?, compositions comprising such antibodies, and methods of use thereof.
    Type: Grant
    Filed: August 4, 2021
    Date of Patent: December 3, 2024
    Assignee: Synthekine, Inc.
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus, Sandro Vivona
  • IL23R BINDING MOLECULES AND METHODS OF USE
    Publication number: 20240376217
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL23R, compositions comprising such antibodies, and methods of use thereof.
    Type: Application
    Filed: May 6, 2024
    Publication date: November 14, 2024
    Inventors: Robert Kastelein, Patrick J. Lupardus, Deepti Rokkam
  • IL10 receptor binding molecules and methods of use
    Patent number: 12139545
    Abstract: Provided herein are IL10R binding molecules that bind to IL10Ra and IL10Rb and comprise an IL10Rb sdAb and an IL10Rb VHH antibody.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: November 12, 2024
    Assignee: Synthekine, Inc.
    Inventors: Robert Kastelein, Mahalakshmi Ramadass, Deepti Rokkam, Patrick J. Lupardus, Sandro Vivona
  • IFNGR binding synthetic cytokines and methods of use
    Patent number: 12122839
    Abstract: Provided herein are IFNGR binding molecules that bind to IFNGR1 and IFNGR2 and comprise an anti-IFNGR2 sdAb and an anti-IFNGR2 VHH antibody.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: October 22, 2024
    Assignee: Synthekine, Inc.
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus
  • IL2RG binding molecules and methods of use
    Patent number: 12077594
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL2Rg, compositions comprising such antibodies, and methods of use thereof.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: September 3, 2024
    Assignee: Synthekine, Inc.
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus, Sandro Vivona
  • ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE
    Publication number: 20240279322
    Abstract: The invention provides isoform-selective anti-TGF? antibodies and methods of using the same. In particular, isoform-selective anti-TGF?2, anti-TGF?3, and anti-TGF?2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGF?-related disorders.
    Type: Application
    Filed: January 23, 2024
    Publication date: August 22, 2024
    Inventors: Wei-Ching Liang, Joseph R. Arron, Daryle DePianto, Wendy Green Halpern, WeiYu Lin, Patrick J. Lupardus, Thirumalai Rajan Ramalingam, Dhaya Seshasayee, Tianhe Sun, Tulika Tyagi, Jia Wu, Yan Wu, Jian Ping Yin
  • Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases
    Patent number: 12018085
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IFNgR2, compositions comprising such antibodies, and methods of use thereof.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: June 25, 2024
    Assignee: Synthekine, Inc.
    Inventors: Robert Kastelein, Patrick J. Lupardus, Deepti Rokkam
  • GP130 Binding Molecules and Methods of Use
    Publication number: 20240199737
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human gp130, compositions comprising such antibodies, and methods of use thereof.
    Type: Application
    Filed: August 4, 2021
    Publication date: June 20, 2024
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus, Sandro Vivona
  • IL23R binding molecules and methods of use
    Patent number: 12012457
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL23R, compositions comprising such antibodies, and methods of use thereof. Further disclosed are sequences of complementarity determining regions (CDR1, CDR2 and CDR3) and polypeptide sequences of human and mouse sdAbs.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: June 18, 2024
    Assignee: Synthekine, Inc.
    Inventors: Robert Kastelein, Patrick J. Lupardus, Deepti Rokkam
  • Isoform-selective anti-TGF? antibodies and methods of use
    Patent number: 11919948
    Abstract: The invention provides isoform-selective anti-TGF? antibodies and methods of using the same. In particular, isoform-selective anti-TGF?2, anti-TGF?3, and anti-TGF?2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGF?-related disorders.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: March 5, 2024
    Assignee: GENENTECH, INC.
    Inventors: Wei-Ching Liang, Joseph R. Arron, Daryle Depianto, Wendy Green Halpern, WeiYu Lin, Patrick J. Lupardus, Thirumalai Rajan Ramalingam, Dhaya Seshasayee, Tianhe Sun, Tulika Tyagi, Jia Wu, Yan Wu, Jian Ping Yin
  • COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRINGS
    Publication number: 20240026014
    Abstract: Provided herein are receptor binding proteins that bind to either natural cytokine receptor pairs or non-natural cytokine receptor pairs to create signaling diversity beyond natural receptor pairings.
    Type: Application
    Filed: August 5, 2021
    Publication date: January 25, 2024
    Inventors: Robert Kastelein, Patrick J. Lupardus, Deepti Rokkam
  • IL12RB1-Binding molecules and methods of use
    Patent number: 11859001
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human 1LI2RM, compositions comprising such antibodies, and methods of use thereof.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: January 2, 2024
    Assignee: Synthekine, Inc.
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus, Sandro Vivona
  • IL28A RECEPTOR BINDING SYNTHETIC CYTOKINES AND METHODS OF USE
    Publication number: 20230391891
    Abstract: Provided herein are IFNlambdaR1 binding molecules that bind to IL10Rb and IL28RA and comprise an anti-IL28RA sdAb 2 and an anti-IL28RA VHH antibody.
    Type: Application
    Filed: August 5, 2021
    Publication date: December 7, 2023
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus
  • IFNGR1 BINDING MOLECULES AND METHODS OF USE
    Publication number: 20230365696
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IFNgR1, compositions comprising such antibodies, and methods of use thereof.
    Type: Application
    Filed: August 5, 2021
    Publication date: November 16, 2023
    Applicant: Synthekine, Inc.
    Inventors: Robert Kastelein, Patrick J. Lupardus, Deepti Rokkam
  • IL12RB2 BINDING MOLECULES AND METHODS OF USE
    Publication number: 20230357414
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL12Rb2, compositions comprising such antibodies, and methods of use thereof.
    Type: Application
    Filed: August 5, 2021
    Publication date: November 9, 2023
    Inventors: Sandro Vivona, Robert Kastelein, Deepti Rokkam, Patrick j. Lupardus
  • CD45 BINDING MOLECULES AND METHODS OF USE
    Publication number: 20230357424
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody that that selectively binds to the extracellular domain of human CD45, compositions comprising such antibodies, methods of use thereof.
    Type: Application
    Filed: August 16, 2021
    Publication date: November 9, 2023
    Inventors: Patrick J. LUPARDUS, Deepti ROKKAM
  • IL10 RECEPTOR BINDING MOLECULES AND METHODS OF USE
    Publication number: 20230322936
    Abstract: Provided herein are IL10R binding molecules that bind to IL10Ra and IL10Rb and comprise an IL10Rb sdAb and an IL10Rb VHH antibody.
    Type: Application
    Filed: February 3, 2023
    Publication date: October 12, 2023
    Inventors: Robert Kastelein, Mahalakshmi Ramadass, Deepti Rokkam, Patrick J. Lupardus, Sandro Vivona
  • IL27RAlpha Binding Molecules and Methods of Use
    Publication number: 20230295314
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL27R?, compositions comprising such antibodies, and methods of use thereof.
    Type: Application
    Filed: August 4, 2021
    Publication date: September 21, 2023
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus, Sandro Vivona
  • IL10RB Binding Molecules and Methods of Use
    Publication number: 20230295315
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL10Rb, compositions comprising such antibodies, and methods of use thereof.
    Type: Application
    Filed: August 5, 2021
    Publication date: September 21, 2023
    Inventors: Robert Kastelein, Sandro Vivona, Deepti Rokkam, Patrick J. Lupardus